Candel Therapeutics Inc. (CADL)
| Bid | 4.98 |
| Market Cap | 234.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.18M |
| EPS (ttm) | -1.74 |
| PE Ratio (ttm) | -2.85 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 5.03 |
| Volume | 811,670 |
| Avg. Volume (20D) | 1,131,720 |
| Open | 4.86 |
| Previous Close | 5.00 |
| Day's Range | 4.81 - 5.02 |
| 52-Week Range | 3.79 - 14.60 |
| Beta | -0.94 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of hi...
Analyst Forecast
According to 4 analyst ratings, the average rating for CADL stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 344.00% from the latest price.
Stock Forecasts
3 weeks ago · proactiveinvestors.com
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a pa...
4 weeks ago · proactiveinvestors.com
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMICandel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung...
1 month ago · proactiveinvestors.com
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trialCandel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with adv...
1 month ago · proactiveinvestors.com
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive...
1 month ago · proactiveinvestors.com
Candel Therapeutics appoints cancer immunology expert to research advisory boardCandel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancrea...
1 month ago · proactiveinvestors.com
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipelineCandel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forwa...
1 month ago · proactiveinvestors.com
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMICandel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectabl...
2 months ago · proactiveinvestors.com
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapyCandel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma ...